Literature DB >> 3366868

Application of optical properties of the Vi capsular polysaccharide for quantitation of the Vi antigen in vaccines for typhoid fever.

A L Stone1, S C Szu.   

Abstract

The capsular polysaccharide of Salmonella typhi and of Citrobacter freundii (Vi) is a linear homopolymer of alpha 1,4-linked N-acetylgalactosaminuronic acid, variably O-acetylated at the C-3 position. Vaccines composed of Vi confer protection against typhoid fever with an efficacy of about 70%; Vi has recently been conjugated to proteins to increase its immunogenicity and effectiveness (I.L. Acharya, R. Tapa, V.L. Gurubacharya, M.B. Shrestha, C.U. Lowe, D.D. Bryla, R. Schneerson, J.B. Robbins, T. Crampton, B. Trollfors, M. Cadoz, D. Schulz, and J. Armand, N. Engl. J. Med. 317:1101-1104, 1987; K.P. Klugman, I. Gilbertson, H.J. Kornhof, J.B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, and J. Armand, Lancet ii:1165-1169, 1987; S.C. Szu, A.L. Stone, J.D. Robbins, R. Schneerson, and J.B. Robbins, J. Exp. Med. 166:1510-1524, 1987). Vi, however, cannot be measured by conventional colorimetric methods. Two optical techniques were adapted to quantitate Vi in vaccines. The first, Fourier-transformed infrared spectroscopy, was performed on salt-free, freeze-dried samples. The intensities of the absorbance peaks of Vi were proportional to the amount of Vi within the range of 0.25 to 2.0 mg. The amount of Vi was determined from integrated absorptions at the 1,235- or 1,417-cm-1 band. The second technique, spectrophotometric titration, was more sensitive than the Fourier-transformed infrared spectroscopy and could be performed on dilute solutions. The metachromatic effect of the reaction between the aromatic cationic dye acridine orange and the carboxyl groups of Vi was quantitative within +/- 2% in the range of 20 to 700 micrograms of Vi per ml. The accuracy of the titration of Vi in the vaccines was within +/- 8%. These two methods may be applicable to measure other capsular polysaccharides in vaccines.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3366868      PMCID: PMC266426          DOI: 10.1128/jcm.26.4.719-725.1988

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  28 in total

1.  The type-specific substance of Hemophilus influenzae, type d: the natural occurrence of glucosamine uronic acid.

Authors:  A R WILLIAMSON; S ZAMENHOF
Journal:  J Biol Chem       Date:  1963-07       Impact factor: 5.157

Review 2.  Vaccines for the prevention of encapsulated bacterial diseases: current status, problems and prospects for the future.

Authors:  J B Robbins
Journal:  Immunochemistry       Date:  1978-11

3.  Aggregation of cationic dyes on acid polysaccharides. I. Spectrophotometric titration with acridine orange and other metachromatic dyes.

Authors:  A L Stone; D F Bradley
Journal:  Biochim Biophys Acta       Date:  1967-10-09

4.  Optical rotary dispersion of mucopolysaccharides. 3. Ultraviolet circular dichroism and conformational specificity in amide groups.

Authors:  A L Stone
Journal:  Biopolymers       Date:  1971       Impact factor: 2.505

5.  Structural components of alginic acid. II. The crystalline structure of poly-alpha-L-guluronic acid. Results of x-ray diffraction and polarized infrared studies.

Authors:  E D Atkins; I A Nieduszynski; W Mackie; K D Parker; E E Smolko
Journal:  Biopolymers       Date:  1973       Impact factor: 2.505

6.  The immunological responses observed in field studies in Africa with group A meningococcal vaccines.

Authors:  E C Gotschlich; M Rey; J Etienne; W R Sanborn; R Triau; B Cvjetanović
Journal:  Prog Immunobiol Stand       Date:  1971

7.  Immunity to disease caused by Hemophilus influenzae type b. II. Specificity and some biologic characteristics of "natural," infection-acquired, and immunization-induced antibodies to the capsular polysaccharide of Hemophilus influenzae type b.

Authors:  R Schneerson; L P Rodrigues; J C Parke; J B Robbins
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

8.  Purification and properties of an acidic polysaccharide isolated from Achromobacter georgiopolitanum.

Authors:  E J Smith
Journal:  J Biol Chem       Date:  1968-10-10       Impact factor: 5.157

9.  Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland.

Authors:  H Peltola; H Käyhty; A Sivonen; H Mäkelä
Journal:  Pediatrics       Date:  1977-11       Impact factor: 7.124

10.  Surface polysaccharide from Staphylococcus aureus M that contains taurine, D-aminogalacturonic acid, and D-fucosamine.

Authors:  D F Liau; M A Melly; J H Hash
Journal:  J Bacteriol       Date:  1974-09       Impact factor: 3.490

View more
  12 in total

1.  Phase I clinical trial of O-acetylated pectin conjugate, a plant polysaccharide based typhoid vaccine.

Authors:  Shousun C Szu; Kimi F-Y Lin; Steven Hunt; Chiayung Chu; Nguyen Duc Thinh
Journal:  Vaccine       Date:  2014-03-21       Impact factor: 3.641

2.  Structure and function relations with a T-cell-activating polysaccharide antigen using circular dichroism.

Authors:  Lori S C Kreisman; Julia H Friedman; Andreea Neaga; Brian A Cobb
Journal:  Glycobiology       Date:  2006-09-21       Impact factor: 4.313

3.  Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi.

Authors:  F Micoli; S Rondini; I Pisoni; D Proietti; F Berti; P Costantino; R Rappuoli; S Szu; A Saul; L B Martin
Journal:  Vaccine       Date:  2010-11-27       Impact factor: 3.641

4.  Characterization of the Salmonella paratyphi C Vi polysaccharide.

Authors:  E M Daniels; R Schneerson; W M Egan; S C Szu; J B Robbins
Journal:  Infect Immun       Date:  1989-10       Impact factor: 3.441

5.  Evaluation of a novel Vi conjugate vaccine in a murine model of salmonellosis.

Authors:  Christine Hale; Frances Bowe; Derek Pickard; Simon Clare; Jean-Francois Haeuw; Ultan Powers; Nathalie Menager; Pietro Mastroeni; Gordon Dougan
Journal:  Vaccine       Date:  2006-03-20       Impact factor: 3.641

6.  Comparative immunogenicities of Vi polysaccharide-protein conjugates composed of cholera toxin or its B subunit as a carrier bound to high- or lower-molecular-weight Vi.

Authors:  S C Szu; X R Li; R Schneerson; J H Vickers; D Bryla; J B Robbins
Journal:  Infect Immun       Date:  1989-12       Impact factor: 3.441

7.  Evaluation of the immunogenicity and biological activity of the Citrobacter freundii Vi-CRM197 conjugate as a vaccine for Salmonella enterica serovar Typhi.

Authors:  Simona Rondini; Francesca Micoli; Luisa Lanzilao; Christine Hale; Allan J Saul; Laura B Martin
Journal:  Clin Vaccine Immunol       Date:  2011-01-19

8.  Relation between structure and immunologic properties of the Vi capsular polysaccharide.

Authors:  S C Szu; X R Li; A L Stone; J B Robbins
Journal:  Infect Immun       Date:  1991-12       Impact factor: 3.441

9.  Structure-function relations of heparin-mimetic sulfated xylan oligosaccharides: inhibition of human immunodeficiency virus-1 infectivity in vitro.

Authors:  A L Stone; D J Melton; M S Lewis
Journal:  Glycoconj J       Date:  1998-07       Impact factor: 2.916

10.  Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines.

Authors:  S C Szu; D N Taylor; A C Trofa; J D Clements; J Shiloach; J C Sadoff; D A Bryla; J B Robbins
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.